News + Resources
Keep up with the latest
Featured
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
All Stories
News
The 20(+1) under 40: Inside the next generation of biotech leaders
April 6, 2021
Endpoints News
Read Now
Press Release
The 20(+1) under 40: Inside the next generation of biotech leaders
April 6, 2021
Endpoints News
Read Now
News
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
April 1, 2021
PMLive
Read Now
Press Release
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
April 1, 2021
PMLive
Read Now
Press Release
Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines
March 31, 2021
Read Now
Press Release
Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines
March 31, 2021
Read Now
News
Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B
March 31, 2021
Genetic Engineering & Biotechnology News
Read Now
Press Release
Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B
March 31, 2021
Genetic Engineering & Biotechnology News
Read Now